Bone Medical (ASX:BNE) has completed a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal under development for the treatment of osteoporosis. [ + ]

Biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 is set to enter Phase I trials at the Gold Coast Hospital. [ + ]

Melbourne-based neurodiagnostic specialist CogState (ASX:CGS) says its sales exceeded AUD$1 million in sales for the 2004-05 fiscal year, up 420 per cent on the previous year, largely through sales to major pharmaceutical companies and research institutions. [ + ]

Rockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006. [ + ]

A team of international scientists – including Australians – has made a breakthrough in solving the problem that had put the development of marine-derived pharmaceuticals on hold for years.

Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths. [ + ]

Sydney-based biopharmaceutical Apollo Life Sciences (ASX:AOP) has made a stellar debut on the ASX, at a 54 per cent premium to its offer price. [ + ]

The Minister of Education, Science and Training, Dr Brendan Nelson has announced that the Australian Government would provide more than A$60.4 million for research in the latest round of the Australian Research Council’s (ARC) Linkage Projects Scheme.

Brisbane's Peplin Biotech (ASX:PEP) has enrolled the last of 60 Australian patients for its Phase IIa clinical trial of its topical PEP005 treatment for actinic keratoses (AKs) -- pre-cancerous, dry, scaly areas of sun-damaged skin. [ + ]

Brisbane biopharma CBio has broken the proverbial bottle of champagne over the bows of its new laboratory and office premises at Brisbane Technology Park, and with Commonwealth P3 grant in hand, is ready to "forge ahead" with developing its novel anti-inflammatory molecule. [ + ]

The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation. [ + ]

Melbourne-based biotech Avexa (ASX:AVX) has been forced to rethink its plans to develop its reformulated hepatitis B candidate AVX491. [ + ]

A $20 million national facility which will help the nation to remain at the cutting edge of gene research has been officially opened at The Australian National University.

Brisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has appointed San Francisco's Burrill and Co as matchmaker to sift its crammed dance card for a partner to take its promising angiogenesis inhibitor PI-88 to the market. [ + ]

Acrux (ASX:ACR) has received a US$1 million milestone payment from Vivus for its estradiol transdermal spray product Evamist, currently in Phase III clinical trials to treat menopausal symptoms in the US, which was due today. [ + ]